Lapatinib and Potential Prognostic Value of EGFR Mutations in a Gynecologic Oncology Group Phase II Trial of Persistent or Recurrent Endometrial Cancer

BACKGROUND: A phase II trial was performed to evaluate the efficacy and safety of the tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and HER2, lapatinib, and to explore EGFR, HER2 (EGFR2), phosphorylated ERK MAP Kinase (pERK), and Ki67 expression, as well as EGFR mutations in p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Leslie, Kimberly K., Sill, Michael W., Lankes, Heather A., Fischer, Edgar G., Godwin, Andrew K., Gray, Heidi, Schilder, Russell J., Walker, Joan L., Tewari, Krishnansu, Hanjani, Parviz, Abulafia, Ovadia, Rose, Peter G.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3518448/
https://ncbi.nlm.nih.gov/pubmed/22885469
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2012.07.127
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados